How common is PMDD? The numbers

PMDD is far less common than general PMS, though it isn't vanishingly rare either. The most cited estimate puts a confirmed diagnosis at about 1.6% of women and girls, with a provisional diagnosis closer to 3.2% (Reilly et al., 2024).

That gap matters more than it might look. A provisional diagnosis usually comes from a single questionnaire or interview, filled out once and scored against DSM-5-TR criteria. A confirmed diagnosis requires daily symptom ratings kept across at least two menstrual cycles, which is a much higher bar to clear and catches fewer people.

Other systematic reviews report a wider range, citing global PMDD prevalence somewhere between 3% and 8%, depending on the population studied and the method used to diagnose it. That spread is one reason PMDD can read as rare in one article and fairly common in another. The difference usually comes down to method, not to how many women are actually affected.

PMS and PMDD are often confused, but they describe different experiences. PMS covers a wide range of physical and emotional symptoms in the one to two weeks before a period, common enough that a 2025 systematic review in Nutrition Reviews put prevalence near 48% of women of reproductive age worldwide. PMDD is a specific DSM-5-TR diagnosis with a stricter symptom list, a required mood symptom, and confirmation through daily tracking over two cycles.

Put in plain terms, roughly one in two women will recognize some PMS symptoms in a given cycle. By comparison, roughly one in 30 to one in 60 will meet the criteria for PMDD, using the confirmed and provisional rates above. The two conditions share some symptoms, but PMDD sits at a much smaller, more specific slice of that larger group. For more on how common PMS itself is, see how common PMS is, in the numbers.

The most recent large analysis, Reilly et al. (2024), pooled existing prevalence studies to produce the 1.6% and 3.2% figures used above. It's the most cited source for PMDD's overall rate right now.

Other large studies approach PMDD from different angles. A 2025 systematic review on trauma exposure in PMDD screened 369 studies and included 27, with 16 used for the numeric estimate, a reminder of how much research sits around PMDD even when prevalence isn't the main question.

At the population level, the Global Burden of Disease Study 2021 tracked thirteen gynecological conditions worldwide from 1990 to 2021. It lists PMS among the conditions driving a rising disease burden in women of childbearing age, but it doesn't track PMDD as its own category, part of why PMDD numbers are harder to pin down globally than PMS numbers. For a broader look at the evidence base, see PMS and PMDD research, summarised.

Good country level data for PMDD specifically is thin. Most of what's available breaks down PMS, not PMDD, since PMS has been studied in more individual countries.

For example, a systematic review and meta-analysis across nine studies in Ethiopia put PMS prevalence at 53%, higher than the roughly 48% global average from a separate 2025 review. That's a PMS figure, not a PMDD one, and the gap shows how much location and study population move the number even within PMS.

Within PMDD research specifically, the picture by age, race or ethnicity is even less complete. A 2023 narrative synthesis of systematic reviews looked for racial and ethnic differences in premenstrual syndrome or PMDD in the United States and found no existing systematic review that met its inclusion criteria, unlike depression or eating disorders, which did have reviews to draw on. Age shows a similar gap. PMDD is generally studied in women of reproductive age, but few of the papers reviewed here break results down by individual age bands within that range. The gap likely reflects a lack of research, not equal impact across every group.

Three things drive most of the spread in PMDD numbers: how the diagnosis was made, who was studied, and how the results were pooled.

Diagnostic method matters most. A provisional diagnosis from a single questionnaire produces the 3.2% figure. A confirmed diagnosis, which requires daily symptom ratings across at least two cycles under DSM-5-TR criteria, produces the lower 1.6% figure. The confirmed rate is stricter by design, so it's always going to come out smaller.

Population and pooling methods add more spread. That same review found wide variability in how much trauma exposure it found across studies (an I-squared of 95%), a sign of how much pooled estimates can swing even within one body of research. When reviews pool studies that used different symptom checklists, different cutoffs and different populations, the combined number reflects all of that variation, not a single clean rate. Knowing this can help you read a headline claiming PMDD affects '1 in 20' or '1 in 100' women with more context, rather than taking either number as the final word.

If the week before your period consistently brings mood symptoms severe enough to disrupt your life, and those symptoms ease within a few days of your period starting, this pattern fits what the research calls PMDD. It doesn't mean you have it. Only two cycles of daily tracking can confirm that.

That tracking is also exactly what turns a provisional estimate into a confirmed one in the research itself. Two cycles is about two months of daily entries, covering the follicular, ovulation, luteal and menstrual phases at least twice each. Writing down what you feel and when gives you and a clinician something concrete to look at instead of guessing. Learn more about what causes PMDD and how PMDD is diagnosed.

Niyora is a PMS and PMDD support app. If you want somewhere to log how a day actually felt while you track those two cycles, Niyora's Moon lets you write what happened, see it from another angle, and calm down before you decide what to say next.